Top 5 articles of the week – Cancer Network

Udhayvir Grewal: Real world post-marketing pharmacovigilance analysis on hematological toxicities in the US

Recent FDA Committee Vote Could Speed Multiple Myeloma Drug Approval

David Steensma: IND application for first type II JAK2 inhibitor to go into clinical trials

Chris Boshoff: The U.S. FDA granted full approval for our therapy developed with our partner Genmab

Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer

U.S. FDA approved the first targeted medicine for the treatment of patients with relapsed or refractory pediatric low-grade glioma – Day One Biopharmaceuticals

Ben Solomon: A timely discussion with Narjust Florez about the ALINA trial

Nitin Jain: The U.S. FDA approves lisocabtagene maraleucel for adults with relapsed or refractory CLL or SLL

Carla Johnson: Cancer patients and doctors have ignited a movement to radically change how new cancer drugs are tested to make them more tolerable